ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
20 January 2023 - 12:30AM
via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical
stage biopharmaceutical company developing therapeutic solutions in
oncology/hematology, CNS, and ophthalmology, today announced that
Dr. Keith McBurnett, Professor of Psychiatry at the University of
California San Francisco, presented the results of the Phase IIa
study of its medical treatment, ABV-1505 ADHD, on January 14, 2023
at the 2023 Conference of The American Professional Society of ADHD
and Related Disorders (APSARD) Poster Session. APSARD is a
world-renowned organization consisting of a broad spectrum of
allied mental health experts working to improve the quality of care
for patients with ADHD through the advancement and dissemination of
research, and evidence-based practices.
The active pharmaceutical ingredient of ABV-1505, PDC-1421, was
used in the Phase IIa study which involved six adult subjects with
confirmed ADHD. Each patient was administered two doses of PDC-1421
(low, 380mg; and high, 760mg) three times a day for four weeks and
a one-week post-treatment follow-up. The study found that
both low and high doses of PDC-1421 were safe, well-tolerated and
efficacious during the treatment and the follow-up period. Dr.
McBurnett’s presentation is available on the APSARD website at
https://apsard.org/2023-conference/ with a Submission ID number
3001531.
As a result of the Phase IIa study results, ABVC is currently
conducting a Phase IIb randomized, double-blind, placebo-controlled
study entitled “A Phase II Tolerability and Efficacy Study of
PDC-1421 Treatment in Adult Patients with Attention-Deficit
Hyperactivity Disorder (ADHD), Part II” that will eventually
involve a total of approximately 100 patients at the University of
California, San Francisco and five research hospitals in
Taiwan.
“We were pleased to have the impressive ABV-1505 ADHD Phase IIa
study results presented by Dr. McBurnett at the 2023 APSARD
Conference,” said Dr. Howard Doong, Chief Executive Officer of the
Company. Dr. Doong further noted that “The ABV-1505 Phase IIb study
is moving along well with enrollments now exceeding more than 40
subjects.”
According to Grand View Research’s market research report, the
ADHD drug market is valued at USD 16.4 Billion in 2018 and expected
to reach USD 24.9 Billion by 2025 with the CAGR of 6.4% over the
forecast period.
(https://www.grandviewresearch.com/industry-analysis/attention-deficit-hyperactivity-disorder-adhd-market)
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company
with an active pipeline of six drugs and one medical device
(ABV-1701/Vitargus) under development. For its drug products, it is
focused on utilizing its licensed technology to conduct
proof-of-concept trials through Phase II of the clinical
development process at world-famous research institutions (such as
Stanford University, University of California at San Francisco, and
Cedars-Sinai Medical Center). For Vitargus, the company intends to
conduct the clinical trials through Phase III at various locations
throughout the globe.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential,” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions, and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified, and, consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to proceed to the next level of the clinical
trials or to market our product candidates. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Contact:Leeds Chow, CFOEmail: leedschow@ambrivis.com
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Apr 2023 to Apr 2024